







### **Global Disclaimer**















- In keeping with our role as a university hospital, we are active in research and receive funding from various sources
- Research is supported by government agencies: Free State of Bavaria, Cancer Aid, DFG, BMBF (DKTK, DZL) and BMU
- For individual research projects and/or meeting presentations and participation in advisory boards, the department is supported by:
  - AstraZeneca, MERCK, MSD, BMS, ViewRay, ELEKTA, Brainlab and C-RAD and OPASCA




















### **Traditional CT-based workflow**



### ELSEVIER

Contents lists available at ScienceDirect

#### Clinical Oncology

CHICOLOGY


journal homepage: www.clinicaloncologyonline.net

## **Adaptive Radiation Therapy (ART) Rationale**

Adaptive Radiotherapy Enabled by MRI Guidance

A. Hunt \*†, V.N. Hansen \*‡, U. Oelfke \*‡, S. Nill \*‡, S. Hafeez \*†





### ELSEVIER

Contents lists available at ScienceDirect

#### Clinical Oncology

journal homepage: www.clinicaloncologyonline.net



## **Adaptive Radiation Therapy Strategies**

Adaptive Radiotherapy Enabled by MRI Guidance

A. Hunt \*†, V.N. Hansen \*‡, U. Oelfke \*‡, S. Nill \*‡, S. Hafeez \*†



ART strategy

intrafraction change

offline ART replanning

online ART replanning

gating, tracking, and realtime ART planning


## Adaptive Radiation Therapy (ART) Workflow


Published in final edited form as: Semin Radiat Oncol. 2019 July; 29(3): 219–227. doi:10.1016/j.semradonc.2019.02.004.

### Practical Clinical Workflows for Online and Offline Adaptive Radiation Therapy


Olga L. Green, Lauren E. Henke, and Geoffrey D. Hugo

Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO





## Online ART Technology






CBCT based MRI based



## Online ART MR-guided RT

### **Benefits of MR-gRT:**

- Superior image quality using MRI
- real-time adaptive radiotherapy
- respiratory-gated radiotherapy
- Potential for dose escalation while sparing organs at risk







## Online ART MR-guided RT

### **Challenges:**

- MRI environment
- Adaptive workflows
- Close interdisciplinary teamwork required
- Longer treatment times
- High costs



Contents lists available at ScienceDirect



#### Radiotherapy and Oncology



journal homepage: www.thegreenjournal.com


Original Article

ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology



Stefanie Corradini <sup>a,\*</sup>, Filippo Alongi <sup>b</sup>, Nicolaus Andratschke <sup>c</sup>, David Azria <sup>d</sup>, Omar Bohoudi <sup>e</sup>, Luca Boldrini <sup>f</sup>, Anna Bruynzeel <sup>e</sup>, Juliane Hörner-Rieber <sup>g</sup>, Ina Jürgenliemk-Schulz <sup>h</sup>, Frank Lagerwaard <sup>e</sup>, Helen McNair <sup>i</sup>, Bas Raaymakers <sup>h</sup>, Tine Schytte <sup>j</sup>, Alison Tree <sup>i</sup>, Vincenzo Valentini <sup>f</sup>, Lotte Wilke <sup>c</sup>, Daniel Zips <sup>k</sup>, Claus Belka <sup>a</sup>


### Clinical MRgRT workflow




Green boxes: workflow pathway, red boxes: suggested professionals (Radiation technologists/therapist (RTT), radiation oncologists (RadOnc) and medical physicists (MedPh))





## Online MRgRT Pancreatic cancer





Plan






1. Fraction

Department of Radiation Oncology, University Hospital, LMU Munich




## Online MRgRT Pancreatic cancer






## Online MRgRT Abdominal Metastases







## Online MRgRT Gyn Boost



- 25.00 Gy 125.0%

  22.00 Gy 110.0%

  20.00 Gy 100.0%

  15.00 Gy 75.0%

  10.00 Gy 50.0%

  7.00 Gy 35.0%
  - EBRT 45Gy
  - MRgRT Boost 4x5Gy (80%ID)
  - PTVopt = 131,35ccm
  - Gesamt-EQD2<sub>10</sub> =  $69,3Gy_{10}$

## Online MRgRT Liver tumors







rticle


### Feasibility and Early Clinical Experience of Online Adaptive MR-Guided Radiotherapy of Liver Tumors

Paul Rogowski <sup>1,\*</sup>, Rieke von Bestenbostel <sup>1</sup>, Franziska Walter <sup>1</sup>, Katrin Straub <sup>1</sup>, Lukas Nierer <sup>1</sup>, Christopher Kurz <sup>1</sup>, Guillaume Landry <sup>1</sup>, Michael Reiner <sup>1</sup>, Christoph Josef Auernhammer <sup>2,3</sup>, Claus Belka <sup>1,4</sup>, Maximilian Niyazi <sup>1,4</sup> and Stefanie Corradini <sup>1</sup>





### Online MRgRT Liver tumors








Articl

### Feasibility and Early Clinical Experience of Online Adaptive MR-Guided Radiotherapy of Liver Tumors


Paul Rogowski <sup>1,\*</sup>, Rieke von Bestenbostel <sup>1</sup>, Franziska Walter <sup>1</sup>, Katrin Straub <sup>1</sup>, Lukas Nierer <sup>1</sup>, Christopher Kurz <sup>1</sup>, Guillaume Landry <sup>1</sup>, Michael Reiner <sup>1</sup>, Christoph Josef Auernhammer <sup>2,3</sup>, Claus Belka <sup>1,4</sup>, Maximilian Niyazi <sup>1,4</sup> and Stefanie Corradini <sup>1</sup>





### **Potential benefits**


### Which could improve patient compliance





### **Patient compliance in MRg ART Factors**

- Education
- Financial support
- Social support



- Duration of treatment
- Number of fractions
- MR enviroment

- ➤ Gender
- **≻**Age
- > Preferences

**Symptoms** 

Comorbidities Claustrophobia

#### Contents lists available at ScienceDirect

#### Radiotherapy and Oncology

journal homepage: www.thegreenjournal.com




ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology




Stefanie Corradini <sup>a.\*</sup>, Filippo Alongi <sup>b</sup>, Nicolaus Andratschke <sup>c</sup>, David Azria <sup>d</sup>, Omar Bohoudi <sup>e</sup>, Luca Boldrini <sup>f</sup>, Anna Bruynzeel <sup>e</sup>, Juliane Hörner-Rieber <sup>g</sup>, Ina Jürgenliemk-Schulz <sup>h</sup>, Frank Lagerwaard <sup>e</sup>, Helen McNair <sup>i</sup>, Bas Raaymakers <sup>h</sup>, Tine Schytte <sup>j</sup>, Alison Tree <sup>i</sup>, Vincenzo Valentini <sup>f</sup>, Lotte Wilke <sup>c</sup>, Daniel Zips <sup>k</sup>, Claus Belka <sup>a</sup>





#### Patient screening for MR-compatibility

- ✓ metal screening
- implant screening
- ✓ pacemaker/ICD screening



### ELSEVIER

#### Contents lists available at ScienceDirect

#### Radiotherapy and Oncology



journal homepage: www.thegreenjournal.com

Original Artic

ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology



Stefanie Corradini <sup>a.e.</sup>, Filippo Alongi <sup>b</sup>, Nicolaus Andratschke <sup>c</sup>, David Azria <sup>d</sup>, Omar Bohoudi <sup>e</sup>, Luca Boldrini <sup>f</sup>, Anna Bruynzeel <sup>e</sup>, Juliane Hörner-Rieber <sup>g</sup>, Ina Jürgenliemk-Schulz <sup>h</sup>, Frank Lagerwaard <sup>e</sup>, Helen McNair <sup>l</sup>, Bas Raaymakers <sup>b</sup>, Tine Schytte <sup>l</sup>, Alison Tree <sup>l</sup>, Vincenzo Valentini <sup>f</sup>, Lotte Wilke <sup>e</sup>, Daniel Zips <sup>b</sup>, Claus Belka <sup>a</sup>



**Online MRgRT** 

**Patient selection criteria** 

- Physically incompatible (i.e. non-MR conditional pacemaker)
- Clinically incompatible (i.e. major psychiatric disorder, severe claustrophobia, inability to understand instructions)
- Borderline compatible (i.e. mild claustrophobia)
- Fully compatible for MRgRT

- Patients who are assessed as incompatible or who refuse oMRgRT treatment, should be directly referred to standard RT delivery units
- **Appropriate interventions** (e.g. psychological intervention, anesthesia, pharmacological or supportive techniques (music, aromatherapy, hypnosis) could be used for borderline compatible patients.

www.redjournal.org

Online MRgRT
Treatment duration

Longer treatment times than in conventional RT

**Physics Contribution** 


#### Role of On-Table Plan Adaptation in MR-Guided Ablative Radiation Therapy for Central Lung Tumors

Check for undates

Tobias Finazzi, MD, Miguel A. Palacios, PhD, Femke O.B. Spoelstra, MD, PhD, Cornelis J.A. Haasbeek, MD, PhD, Anna M.E. Bruynzeel, MD, PhD, Ben J. Slotman, MD, PhD, Frank J. Lagerwaard, MD, PhD, and Suresh Senan, MRCP, FRCR, PhD

Department of Radiation Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, The Netherlands

Received Dec 10, 2018. Accepted for publication Mar 20, 2019.





LMU	Mean treatment time ADAPTIVE	43 Min
Mean treatment time Non-Adaptive		23 Min



## Online MRgRT Bore size

- Limited bore size in all available systems <70cm
- Length of tunnel (232cm) risk for claustrophobia





Strahlenther Onkol (2020) 196:691-698

Mutlay Sayan<sup>1</sup>\*, Ilkay Serbez<sup>2</sup>, Bilgehan Teymur<sup>2</sup>, Gokhan Gur<sup>2</sup>, Teuta Zoto Mustafayev<sup>2</sup>, Gorkem Gungor<sup>2</sup>, Banu Atalar<sup>2</sup> and Enis Ozyar<sup>2</sup>\*

Patient-Reported Tolerance of Magnetic Resonance-Guided

**Radiation Therapy** 

frontiers in Oncology

acceptance of magnetic resonance-guided radiotherapy in Germany

Sebastian Klüter<sup>1,2,3</sup> · Sonja Katayama<sup>1,2,3</sup> · C. Katharina Spindeldreier<sup>1,2,3</sup> · Stefan A. Koerber<sup>1,2,3</sup> ·

Gerald Major<sup>1,2,3</sup> · Markus Alber<sup>1,2,3</sup> · Sati Akbaba<sup>1,2,3</sup> · Jürgen Debus<sup>1,2,3,4,5</sup> · Juliane Hörner-Rieber<sup>1,2,3,4</sup>







FIGURE 1 | Patient set-up during magnetic resonance-guided radiation therapy.



## Visual Feedback oMRgRT

Received: 24 April 2020 Revised: 12 July 2020 Accepted: 29 July 2020


DOI: 10.1002/acm2.13016

#### TECHNICAL NOTE

WILEY


### Direct tumor visual feedback during free breathing in 0.35T MRgRT

Taeho Kim $^1$  | Benjamin C. Lewis $^1$   $_{\bigcirc}$  | Alex Price $^1$  | Thomas Mazur $^1$  | H. Michael Gach $^{1,2}$  | Justin C. Park $^1$  | Bin Cai $^1$  | Erin Wittland $^1$  | Lauren Henke $^1$  | Hyun Kim $^1$  | Sasa Mutic $^1$  | Olga Green $^1$ 





- Visual feedback improved:
  - Smaller tumor motion outsite gating contour
  - Beam on time: 43.9% without vs 48.0% with visual guidance (P = 0.34)



Received: 24 April 2020 Revised: 12 July 2020 Accepted: 29 July 2020

DOI: 10.1002/acm2.13016

#### TECHNICAL NOTE

WILEY

### Direct tumor visual feedback during free breathing in 0.35T MRgRT

```
Taeho Kim^1 | Benjamin C. Lewis^1 _{\bigcirc} | Alex Price^1 | Thomas Mazur^1 | H. Michael Gach^{1,2} | Justin C. Park^1 | Bin Cai^1 | Erin Wittland^1 | Lauren Henke^1 | Hyun Kim^1 | Sasa Mutic^1 | Olga Green^1
```

### oMRgRT

### **Patient acceptance**

#### 43 patients – PROM

#### 65% complaint rate of at least 1 item

- > cold temperature
- > Noise
- Duration of treatment
- > Paresthesia
- > uncomfortable positioning

#### **ORIGINAL ARTICLE**



### First prospective clinical evaluation of feasibility and patient acceptance of magnetic resonance-guided radiotherapy in Germany

Sebastian Klüter<sup>1,2,3</sup> · Sonja Katayama<sup>1,2,3</sup> · C. Katharina Spindeldreier<sup>1,2,3</sup> · Stefan A. Koerber<sup>1,2,3</sup> · Gerald Major<sup>1,2,3</sup> · Markus Alber<sup>1,2,3</sup> · Sati Akbaba<sup>1,2,3</sup> · Jürgen Debus<sup>1,2,3,4,5</sup> · Juliane Hörner-Rieber<sup>1,2,3,5</sup>

#### Table 4 Results of the patient-reported outcome questionnaires

How do you rate	After the first fraction $(n=34)$	At the end of treatment $(n=34)$	p-value
	Mean (range)		
the treatment at the MRlinac in total?	1.3 (1-4)	1.4 (1-3)	0.739
the information provided by the staff before treatment?	1.1 (1-2)	1.1 (1-2)	1.000
the friendliness of the staff?	1.0 (1-2)	1.0 (1-2)	0.317
the duration of treatment?	2.2 (2-5)	2.1 (2-4)	0.741
the size of the MRI bore?	1.9 (1-4)	1.8 (1-4)	1.000
the positioning during RT?	2.2 (1-4)	2.2 (1-4)	0.604
having to lie still?	2.0 (1-3)	1.8 (1-4)	0.662
the noise in the MRI?	2.1 (1-4)	2.0 (1-3)	0.817
the temperature in the MRI?	3.6 (1-4)	3.4 (1-3)	0.067
the local temperature of your body parts?	3.5 (1-3)	3.2 (1-4)	0.302
potential tingling sensations in your fingers and toes?	1.9 (1-4)	1.7 (1-4)	0.090
the breathing instructions?	1.1 (1-3)	1.2 (1-2)	0.102
holding your breath during RT?	1.4 (1-3)	1.5 (1-3)	0.305
Were you anxious during treatment?	1.4 (1-3)	1.3 (1-3)	0.157
Respiratory gated dose delivery $(N=22)$			
Was it difficult to control the target by holding your breath?	1.3 (1-3)	1.2 (1-2)	0.739
Was it confronting to watch your tumor on the monitor?	1.2 (1-2)	1.1 (1-2)	0.564
How did you like the possibility to have an active role in control- ling the duration of treatment?	1.2 (1–2)	1.1 (1-2)	1.000





### Patient-Reported Tolerance of Magnetic Resonance-Guided Radiation Therapy

Mutlay Sayan<sup>1</sup>\*, Ilkay Serbez<sup>2</sup>, Bilgehan Teymur<sup>2</sup>, Gokhan Gur<sup>2</sup>, Teuta Zoto Mustafayev<sup>2</sup>, Gorkem Gungor<sup>2</sup>, Banu Atalar<sup>2</sup> and Enis Ozyar<sup>2</sup>\*

- 90 patients PROM
- Main complaints: cold temperature (61%), paresthesia (57%)
- Anxiety (45%) was significantly decreased after completion of the treatment (p=0.01)

TABLE 3   Result of the patient reported outcomes.					
How do you rate	After the first fraction, Mean (SD)	After the last fraction, Mean (SD)	p		
your anxiety level during treatment?	1.44 (0.656)	1.26 (0.567)	0.01		
the duration of treatment?	2.73 (0.747)	2.80 (0.741)	0.38		
the sensation of local heat?	1.14 (0.436)	1.12 (0.364)	0.63		
the feeling of cold during treatment?	1.83 (0.604	1.74 (0.728)	0.19		
dizziness?	1.63 (0.661)	1.53 (0.640)	0.09		
potential tingling sensations in your extremities	1.78 (0.790)	1.70 (0.729)	0.22		
a metallic taste?	1.03 (0.184)	1.07 (0.252)	0.32		
perceptions of light flashes?	1.04 (0.207)	1.04 (0.208)	0.99		
the noise in the MRI?	1.66 (0.823)	1.53 (0.694)	0.26		
Was music relaxing?	3.21 (1.258)	3.10 (1.274)	0.22		
Was it difficult to control the target by holding your breath?	2.00 (0.788)	1.86 (0.805)	0.21		
Was it disturbing to see your tumor during treatment?	1.34 (0.745)	1.25 (0.606)	0.35		
Did you like having an active role during treatment?	2.96 (0.852)	3.11 (0.867)	0.15		
Did you worry about your contribution to the treatment?	1.32 (0.640)	1.22 (0.623)	0.20		



### oMRgRT

### Can we also treat elderly patients?



## oMRgRT Elderly patients

- 30 patients >75 years. Mean age was  $81.4 \pm 3.4$  years
- MASTER scoring system for patient selection

Score <4



Table 3. MASTER score items and corresponding values.

Condition	MASTER score value	
MRI incompatibility (i.e. pacemaker)	4	
Major cognitive impairment	4	
Severe claustrophobia	4	
ECOG PS value ≥3	3	
ECOG PS value ≥2	2	
Mild cognitive impairment	1	
Frailty	1	
Essential tremor	1	
Visual deficit	1	
Deafness	1	
Gated treatment foreseen	T	
Urinary or fecal incontinence	1	

ECOG PS: Eastern Cooperative Oncology Group Performance Status; MRI: magnetic resonance imaging.





Tumori Journal
2021, Vol. 107(1) 26-31
© Fondazione IRCCS Istituto
Nazionale dei Tumori 2020
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/0300891620920709
journals.sagepub.com/home/tmj

SSAGE

Luca Boldrini<sup>1,2</sup>, Giuseppe F. Colloca<sup>2</sup>, Emanuele Villani<sup>3</sup>, Giuditta Chiloiro<sup>1,2</sup>, Andrea Bellieni<sup>3</sup>, Stefania Manfrida<sup>1</sup>, Francesco Cellini<sup>1</sup>, Maria Antonietta Gambacorta<sup>1,2</sup> and Vincenzo Valentini<sup>1,2</sup>

Magnetic resonance-guided

**MASTER** scoring system

radiotherapy feasibility in elderly

cancer patients: proposal of the

Score > 4 Clinically incompatible



## oMRgRT Elderly patients

- 40 patients mean age was 73 years (65-85)
- Quality of life
- "SBRT is feasible, safe and does not impact QoL"

Patients	40
Lesions (n, %):	42
Age	
Median (years)	73
Range (years)	65-85
Gender $(n, \%)$	
Male	38 (95%)
Female	2 (5%)
Treatment site $(n, \%)$	
Prostate	13 (30.9%)
Prostate + seminal vesicles	14 (33.3%)
Prostate bed	1 (2.4%)
Pelvic lymph node	8 (19.1%)
Abdominal lymph node	4 (9.5%)
Bones	2 (4.8%)
Overall treatment time	
Median (minutes)	41
Range (minutes)	20-61

Journal of Cancer Research and Clinical Oncology https://doi.org/10.1007/s00432-020-03230-w

#### ORIGINAL ARTICLE - CLINICAL ONCOLOGY



### Feasibility and safety of 1.5 T MR-guided and daily adapted abdominal-pelvic SBRT for elderly cancer patients: geriatric assessment tools and preliminary patient-reported outcomes

Rosario Mazzola¹ · Vanessa Figlia¹ · Michele Rigo¹ · Francesco Cuccia¹ · Francesco Ricchetti¹ · Niccolò Giaj-Levra¹ · Luca Nicosia¹ · Claudio Vitale¹ · Gianluisa Sicignano¹ · Antonio De Simone¹ · Stefania Naccarato¹ · Ruggero Ruggieri¹ · Filippo Alongi¹,²




## Patient Compliance Online MRgRT





### The patient perspective







#### **Adaptive Radiotherapy:**

- RT plan adapted to account for internal anatomical changes
- Potential benefits of ART → could improve patient compliance
- Patient selection in oMRgRT is key to success
- Measures to improve patient compliance



# Thank you For your attention!



